"Besuchsregeln – bis auf weiteren gilt an allen Standorten der Salzburger Landeskliniken: • Aufgrund der COVID-Pandemie gelten derzeit eingeschränkte Besuchsregeln. Bitte informieren Sie sich auf unserer Homepage über mögliche Ausnahmen. Patientenversorgung, Prävention und Rehabilitation, Forschung, Lehre und Ausbildung Ob ÄrztInnen, Pflegemitarbeiter oder sonstige Mitarbeiter im Landeskrankenhaus, sie alle sehen es als selbstverständlich, bei der Erbringung von medizinischen Spitzenleistungen den Menschen in seiner Ganzheit zu sehen. Im Mittelpunkt steht immer der Mensch, der von den MitarbeiterInnen des Krankenhauses mit Respekt und Würde behandelt wird."

During the past decade, Landeskrankenhaus Salzburg conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 15 clinical trials were completed, i.e. on average, 30.6% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 7 clinical trials were completed. i.e. 31.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Landeskrankenhaus Salzburg" #1 sponsor was "Amgen" with 15 trials, followed by "Celgene" with 10 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Incyte Corporation" with 4 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Landeskrankenhaus Salzburg" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Alliance for Clinical Trials in Oncology" with 1 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 43 trials.

According to Clinical.Site data, the most researched conditions in "Landeskrankenhaus Salzburg" are "Crohn Disease" (4 trials), "Multiple Myeloma" (4 trials), "Ulcerative Colitis" (4 trials), "Chronic Lymphocytic Leukemia" (3 trials) and "Lymphoma, Non-Hodgkin" (3 trials). Many other conditions were trialed in "Landeskrankenhaus Salzburg" in a lesser frequency.

Most popular intervention types in "Landeskrankenhaus Salzburg" are "Drug" (58 trials), "Other" (8 trials), "Biological" (3 trials), "Device" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Dexamethasone" (6 trials), "Gemcitabine" (5 trials), "Lenalidomide" (5 trials) and "Pembrolizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Landeskrankenhaus Salzburg" are 61 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Landeskrankenhaus Salzburg". undefined are not yet recruiting, 21 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Landeskrankenhaus Salzburg, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Landeskrankenhaus Salzburg, 13 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".